Drug treatment of elevated blood pressure
- Mark Nelson
- Aust Prescr 2010;33:108-12
- 1 August 2010
- DOI: 10.18773/austprescr.2010.055
The decision on when to start drugs for the treatment of elevated blood pressure should be determined by an individual's absolute risk of having an adverse cardiovascular event. The choice of drug depends on its safety and effectiveness and its indications and contraindications for individual patients. Most patients will require two or more drugs to reach their target blood pressure.The main classes of antihypertensive drugs are equally effective at reducing blood pressure, but beta blockers are no longer recommended as first-line treatment for most patients.
All patients with elevated blood pressure should be encouraged to have a healthy lifestyle.1 Although there are benefits from weight loss, salt and alcohol reduction and exercise, these lifestyle changes may be insufficient to control a patient's blood pressure. This leaves them at risk of coronary heart disease, stroke and renal failure. If the high blood pressure is confirmed by accurate measurements on several occasions, drug treatment should be considered.
Drug treatment for elevated blood pressure should not be based solely on accurate blood pressure readings. It should also consider an individual's absolute cardiovascular risk – their risk of having a stroke or myocardial infarction over a specified period of time, usually five years.2 An absolute risk calculator can be used to identify who is most likely to benefit from treatment.3 The previous underestimation of risk in Aboriginal and Torres Strait Islander people by such calculators has been addressed in the recently published Australian risk calculator.4–6
Immediate treatment to lower blood pressure is recommended for patients with confirmed hypertension (multiple measures on at least two separate occasions):
Patients with associated conditions (for example, stroke or myocardial infarction) or evidence of end-organ damage (for example, microalbuminuria, left ventricular hypertrophy) also need urgent treatment (Fig. 1).
Once the decision has been made to start drug therapy, the choice of antihypertensive drug should be based on the patient's age and the presence of associated clinical conditions or end-organ damage. The presence of other diseases may favour or limit the use of particular drug classes and there may be potential interactions with other drugs (Table 1). Cost and the ease of adhering to treatment should also be considered. Antihypertensive drugs in different classes have similar efficacy. In uncomplicated cases the recommendation is to start with an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor antagonist, calcium channel blocker or diuretic (in the aged).2 Beta blockers are no longer recommended as first-line treatment for uncomplicated high blood pressure as meta-analyses show they have an adverse relative risk of stroke and new onset diabetes compared to other drugs.78
A patient's comorbidity helps to determine which blood pressure to aim for. In uncomplicated hypertension the target should be 140/90 mmHg or lower if tolerated. The target is under 130/80 mmHg in patients with end-organ damage or conditions such as diabetes, and under 125/75 mmHg in patients with proteinuria (>1 g/day).
It is important that patients be treated to reach their recommended blood pressure. Failure to do so leaves patients at significant residual adverse risk.
Start with the lowest recommended dose of the selected drug and review the patient after six weeks. If the drug is not well tolerated or is ineffective, change to a drug of a different class. If the target blood pressure is still not reached, add a further drug from a different pharmacological class at a low dose, rather than increasing to the maximum dose of the first drug.
BP blood pressure
SBP systolic blood pressure
DBP diastolic blood pressure
* For example, diabetes (strict glycaemic control lowers cardiovascular risk), lipid disorders (cholesterol-lowering therapy reduces the risk of primary and secondary coronary events). See National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Position statement on lipid management 2005 www.heartfoundation.org.au.
† For Aboriginal and Torres Strait Islander adults, consider managing as though at a higher risk level
‡ Continue lifestyle modification, monitor blood pressure and reassess absolute cardiovascular risk regularly. Note that patients with mild hypertension will require antihypertensive drug treatment if their absolute risk of cardiovascular disease is elevated due to changes in other risk factors.
|Figure is adapted and reproduced with the permission of the Heart Foundation|
|Condition||Potentially beneficial||Potentially harmful|
|Angina||Beta blockers (except oxprenolol, pindolol), calcium channel blockers, ACE inhibitors|
Remodelling: ACE inhibitors, angiotensin receptor antagonists*
Rate control: verapamil, diltiazem, beta blockers
|Asthma/COPD||Cardioselective beta blockers (e.g. atenolol, metoprolol): use cautiously in mild–moderate asthma/COPD only||Beta blockers (except cardioselective drugs)|
|Bradycardia, second- or third-degree atrioventricular block||Beta blockers, verapamil, diltiazem|
|Depression||Beta blockers, clonidine, methyldopa, moxonidine|
|Heart failure||ACE inhibitors, angiotensin receptor antagonists,*thiazide diuretics, beta blockers†
(bisoprolol, carvedilol, metoprolol controlled release), spironolactone
|Calcium channel blockers (especially verapamil, diltiazem)||Alpha blockers in aortic stenosis Beta blockers in uncontrolled heart failure|
|Post myocardial infarction||Beta blockers (except oxprenolol, pindolol), ACE inhibitors, eplerenone|
|Pregnancy§||ACE inhibitors, angiotensin receptor antagonists, diuretics, calcium channel blockers (before 22 weeks gestation), atenolol|
|Chronic kidney disease||ACE inhibitors, angiotensin receptor antagonists*|
|Tight bilateral renal artery stenosis (unilateral in patient with solitary kidney)||ACE inhibitors, angiotensin receptor antagonists|
|Post stroke||ACE inhibitors, angiotensin receptor antagonists, low-dose thiazide-like diuretics|
|Type 1 or type 2 diabetes with proteinuria or microalbuminuria||ACE inhibitors, angiotensin receptor antagonists*||Beta blockers, thiazide diuretics‡|
|ACE angiotensin-converting enzyme||COPD chronic obstructive pulmonary disease|
* Careful monitoring of kidney function is required if a combination of ACE inhibitors and angiotensin receptor antagonists is used
† Particular beta blockers are now indicated in the treatment of heart failure. See the Heart Foundation Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006 (available at www.heartfoundation.org.au).
‡ When used in combination with an ACE inhibitor, may be beneficial in type 2 diabetes
§ Currently under review by the Heart Foundation
Table is adapted and reproduced with the permission of the Heart Foundation
This treatment approach maximises efficacy while minimising adverse effects. Titrate the dose of one drug then the other until the target blood pressure is reached. Additional drugs may be required.
Attaining and maintaining the target blood pressure may be assisted by:
or angiotensinreceptor antagonist
|plus||calcium channel blocker||Diabetes or dyslipidaemia|
|plus||thiazide diuretic||Heart failure or post stroke|
|plus||beta blocker||Post myocardial infarction or heart failure|
|Beta blocker||plus||dihydropyridine calcium channel blocker||Coronary heart disease|
|Thiazide diuretic||plus||calcium channel blocker|
|plus||beta blocker||Not with glucose intolerance, metabolic syndrome or diabetes|
|Combinations to avoid||Recommendation|
or angiotensin receptor antagonist
|plus||potassium-sparing diuretic||Avoid because of risk of hyperkalaemia|
|Verapamil||plus||beta blocker||Avoid because of risk of heart block|
|ACE inhibitor||plus||angiotensin receptor antagonist||In a large trial, combination therapy did not reduce cardiovascular death or morbidity in patients with vascular disease or diabetes while increasing the risk of hypotensive symptoms, syncope and renal dysfunction|
ACE angiotensin-converting enzyme
Table is adapted and reproduced with the permission of the Heart Foundation
Approximately 60% of patients with elevated blood pressure will not achieve their blood pressure targets with monotherapy. Most patients will require a combination of two or more drugs to achieve adequate blood pressure control. There are several effective combinations (Table 2). In the ACCOMPLISH trial an ACE inhibitor and calcium channel blocker combination reduced cardiovascular events more than a combination of the ACE inhibitor with a diuretic.9
Drug treatment is usually lifelong, as age is the most important determinant of adverse risk, unless the blood pressure is well controlled by profound lifestyle changes.10 If blood pressure is normal and stable, the interval between visits can be lengthened, for example, review every three months for the next 12 months and six-monthly thereafter.
If treatment is stopped, the patient's blood pressure should be checked regularly. Patients should continue the lifestyle changes and agree to resume drug treatment if their blood pressure rises again.
Failure to control blood pressure can be due to a wide range of prescriber, patient, healthcare system and drug related factors. If blood pressure remains above the target despite maximal doses of at least two appropriate drugs after a reasonable period, consider the following potential explanations:
In the elderly, isolated elevated systolic blood pressure is more prevalent due to large vessel stiffness associated with ageing. Calcium channel blocker- or diuretic-based drug treatment is recommended.
In the very elderly, the recommended blood pressure targets may be difficult to achieve due to comorbidity, reduced physiological function and polypharmacy. However, the elderly are most at risk of adverse cardiovascular events and trials have shown that drug therapy is just as effective in advanced age. The HYpertension in the Very Elderly Trial (HYVET) studied patients aged 80 years or more (mean age 83.6 years). It showed a 39% relative reduction in the rate of death from stroke, a 21% reduction in the rate of death from any cause, a 23% reduction in the rate of death from cardiovascular causes and a 64% reduction in the rate of heart failure for those on active treatment versus placebo. Fewer serious adverse events were reported in the active treatment group so concerns about causing more harm than good are allayed.11
Drug therapy is warranted in individuals with a high risk of adverse cardiovascular events. It does not obviate the need for behavioural modification. All classes of antihypertensive drugs have similar efficacy, but specific recommendations are made according to the patient's characteristics. Whichever drug is started, it is important to treat until the target blood pressure is reached. Usually more than one drug is required to reach the target.
Professor Nelson has participated in trials that have received funding from SmithKline Beecham, AstraZeneca, Bayer, Sanofi-Aventis, Merck Sharpe and Dohme, Pfizer, Servier Laboratories and Bristol-Myers Squibb. He has served on advisory boards for Sanofi-Aventis, Novartis, Schering-Plough and Solvay Pharmaceuticals, prepared educational material for Servier Laboratories, AstraZeneca and Bristol-Myers Squibb and received conference and travel support from Bayer HealthCare AG, Novartis and Sanofi-Aventis.
The following statements are either true or false.
1. Isolated systolic hypertension does not require treatment if the diastolic blood pressure is under 70 mmHg.
2. When there is no response to the initial dose of an antihypertensive drug, it should be titrated to its maximum dose before switching to another drug.
Answers to self-test questions
Professor and Chair, Discipline of General Practice, School of Medicine, University of Tasmania, Hobart
Professorial Research Fellow and Senior Member, Menzies Research Institute, University of Tasmania, Hobart